The primary objective ofthe Glioma SPORE Career Development Program (CDP) is to attract talented new investigators to translational glioblastoma research. Potential CDP awardees include junior faculty beginning their careers or established faculty members in other fields who wish to redirect their interests and efforts to glioblastoma research. We will establish a comprehensive, system-wide process for solicitation of CDP applications and an expert-based review process to select the most meritorious applicants. The CDP program faculty will consist of a multidisciplinary cohort of experienced, senior mentors for CDP awardees. The CDP will provide limited-duration funding for promising, junior translational investigators who are focused on glioma research. The program will provide support, mentoring and monitoring for CDP awardees. We will establish a monitoring process to measure progress and outcomes of CDP awardees and the CDP program. We will carefully monitor the progress of awardees through clearly enumerated metrics. The CDP will be assessed on an annual basis by the internal and external advisory boards. The CDP will leverage institutional resources to support and enhance the success of the program.

Public Health Relevance

The Career Development Program will provide research support for junior or new investigators in the field of brain tumor research. Through support, mentoring and monitoring it is anticipated that the program will enable awardees to embark on sucessful careers in brain tumor research that will ultimately benefit patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA165962-01A1
Application #
8588506
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2013-09-19
Project End
2018-07-31
Budget Start
2013-09-19
Budget End
2014-07-31
Support Year
1
Fiscal Year
2013
Total Cost
$58,623
Indirect Cost
$15,459
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Peterson, Teresa E; Kirkpatrick, Nathaniel D; Huang, Yuhui et al. (2016) Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci U S A 113:4470-5
Kloepper, Jonas; Riedemann, Lars; Amoozgar, Zohreh et al. (2016) Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A 113:4476-81
Flavahan, William A; Drier, Yotam; Liau, Brian B et al. (2016) Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 529:110-4
Curry Jr, William T; Gorrepati, Ramana; Piesche, Matthias et al. (2016) Vaccination with Irradiated Autologous Tumor Cells Mixed with Irradiated GM-K562 Cells Stimulates Antitumor Immunity and T Lymphocyte Activation in Patients with Recurrent Malignant Glioma. Clin Cancer Res 22:2885-96
Stevens, Mark M; Maire, Cecile L; Chou, Nigel et al. (2016) Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat Biotechnol 34:1161-1167
Verreault, Maite; Schmitt, Charlotte; Goldwirt, Lauriane et al. (2016) Preclinical Efficacy of the MDM2 Inhibitor RG7112 in MDM2-Amplified and TP53 Wild-type Glioblastomas. Clin Cancer Res 22:1185-96
Ni, Jing; Ramkissoon, Shakti H; Xie, Shaozhen et al. (2016) Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med 22:723-6
Tateishi, Kensuke; Iafrate, A John; Ho, Quan et al. (2016) Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma. Clin Cancer Res 22:4452-65
Cizmecioglu, Onur; Ni, Jing; Xie, Shaozhen et al. (2016) Rac1-mediated membrane raft localization of PI3K/p110β is required for its activation by GPCRs or PTEN loss. Elife 5:
Fathi, Amir T; Nahed, Brian V; Wander, Seth A et al. (2016) Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma. Oncologist 21:214-9

Showing the most recent 10 out of 44 publications